Immunotherapy with monoclonal antibodies blocking the interaction between the receptors and their ligands in the tumor itself or in the draining lymph node has been shown to enhance priming of anti-tumor CD4 and CD8 T cells and to release TILs from inhibition in animal models as well as in human [17]. This evidence concerns the gene CD8A and neoplasm.